Rezolute reports fiscal 2026 results and clinical updates

Rezolute, Inc. has reported its fourth quarter and full fiscal year 2026 financial results alongside a business update regarding its clinical progress. The company, which focuses on treating refractory hypoglycemia caused by hyperinsulinism, is currently conducting the upLIFT Phase 3 study for tumor-related hyperinsulinism.

Interim data from the upLIFT study indicates that of the participants enrolled, seven have met the responder criterion for the study’s primary endpoint. These participants achieved a complete discontinuation of intravenous glucose requirements following the administration of ersodetug. Topline results for the study are expected before the end of 2026.

In separate market news, HC Wainwright raised its price target for Rezolute (NASDAQ: RZLT) from $5.00 to $10.00, maintaining a “buy” rating. This adjustment suggests a potential upside of approximately 147% from the company’s previous closing price.